Adult Clinical Trials

Genitourinary Cancers - Prostate cancer and cancers of the kidney, bladder, and male organs

If you need additional information about any of the trials, please call the GU Oncology Adult Clinical Trials team at 919.681.1030.

15 trials identified.

Whole Blood from Healthy Volunteers for the Study of Circulating Tumor Cells
Phase: Phase II
Sponsor: PI initiated
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00027680

Evaluation of lymph node metastases in men undergoing treatment with sipuleucel-T for metastatic castrate-resistant prostate cancer
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Brant Inman
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.9822
Reference Number: 00047231

A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients with Castration-Resistant Prostate Cancer
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Daniel George
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00048629
View this trial at ClinicalTrials.gov

Molecular mechanisms underlying prostate cancer disparities.
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Steven Patierno
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00053535

EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination with Conventional Androgen Deprivation Therapy for Hormone Nave Prostate Cancer
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Michael Harrison
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00053924
View this trial at ClinicalTrials.gov

PEAX: Men with Metastatic Castrate-Resistant Prostate Cancer Treated with Either Sipuleucel-T (Provenge), Enzalutamide (Xtandi) or Abiraterone Acetate (Zytiga) Undergoing Cardiopulmonary EXercise Testing
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Michael Harrison
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00058229
View this trial at ClinicalTrials.gov

Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00063296

A Randomized Phase 2 Study of Sipuleucel-T with or without Radium-223 in Men with Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer
Phase: Phase II
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00065532
View this trial at ClinicalTrials.gov

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects with Metastatic Castrate-Resistant Prostate Cancer
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00066478
View this trial at ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of a Vaccine-Based Immunotherapy Regimen (VBIR) for Prostate Cancer (Pf-06753512)
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Tian Zhang
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00067872
View this trial at ClinicalTrials.gov

A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS)
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Thomas Polascik
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00069229

A Phase Ib, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer Who Have Progressed Following Treatment With An Androgen Pathway Inhibitor
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Research Office
Phone: 919.681.1030
Reference Number: 00072263
View this trial at ClinicalTrials.gov

A Multinational, Phase 3, Randomized, Double-blind, Placebo- controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Andrew Armstrong
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00073953
View this trial at ClinicalTrials.gov

A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Megan Diehl
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00074533
View this trial at ClinicalTrials.gov

Exploring relevant immune-based biomarkers and circulating tumor cells during treatment with immune checkpoint inhibitors in genitourinary malignancies
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Tian Zhang
Contact: GU Oncology Clinical Trials Office
Phone: 919.681.1030
Reference Number: 00076768